Enhanced Mobilisation Service
NHS biosimilar switching
Join the NHS Trusts and Health Boards across the UK who have chosen Sciensus to manage their programmes and patient and biosimilar transitions.
How does the Sciensus NHS biosimilar switching service work?
In a landscape where capacity is more of a concern than ever, transitioning patients to an alternative medicine can significantly reduce NHS workload. Sciensus makes migrating patients between products or service provider easy. The Sciensus NHS biosimilar switching process was developed using feedback from our NHS partners, to now offer innovative, digitally enabled solutions to specifically decrease the demand and the administrative burden on the NHS and manage their biosimilar switch with ease.
Since 2018, Sciensus have had a dedicated Mobilisation Team to support with conducting NHS biosimilar switching and provider switches. Within 12 months, Sciensus migrated over 40,000 patients, met NHS cost saving targets, minimised workload and delivered a seamless patient experience. Sciensus has continued to develop our NHS offering in line with the changing requirements of the NHS and their patients.
How can you and your team benefit from using Sciensus Mobilisation Service?
- A seamless experience when switching to an alternative medicine
- Expedited switch to allow patients to transition to more cost-effective medicines sooner
- Streamlined Sciensus onboarding capability allows multiple Trusts to switch at pace simultaneously
- Market-leading proposition achieved through collaborative work between Sciensus and the NHS to deliver valuable, innovative solutions and increase market share
It is an amazing service Sciensus have put together, it has been a well-run, organised offering, that has done exactly what it set out to do.
Kathrine Wood, Pharmacy Homecare Services Manager
Read more about…
Blogs/Articles
EMA orphan drug designation
Gaining orphan drug designation from the European Medicines Agency (EMA) is essential for any company seeking to market a new…
Blogs/Articles
Four considerations before collecting real-world data in your EAP
Early access programs (EAPs) for rare disease medications present a valuable opportunity for biotechs to collect real-world data (RWD). In…
Blogs/Articles
The increasing importance of real-world data for the EMA
Over recent years, real-world data (RWD) has become a critical element of the development and commercialisation of medications. RWD includes…